GA29145: An Open‐Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III Protocol GA29144

May 22, 2015
Gastroenterology - Stomach
Principal Investigator: Nirmal Kaur, MD

This is an open‐label extension (OLE) and safety‐monitoring (SM) study called JUNIPER and is divided into two parts:

  • Part 1 (OLE) will evaluate the long‐term safety and efficacy of etrolizumab subcutaneous injections (under the skin) in treating your Crohn’s disease and may be open to you if you are eligible to receive etrolizumab in this study. Open‐label means that both you and your study doctor will know that you are getting etrolizumab.
  • Part 2 (SM), will assess the long‐term safety of etrolizumab. In Part 2, you will not receive etrolizumab and you will be followed for about 2 years after your last dose of etrolizumab. During Part 2 (SM), your study doctor will decide what treatment for your Crohn’s disease is best for you.

Please contact us for a full list of criteria.